

Advancing novel and nextgeneration compounds to address both orphan and large oncology indications

Nasdaq: SLRX

December 2022

Non Confidentia

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements may be identified by terms such as "will," "future," "believe," "developing," "expect," "may," "progress," "potential," "could," "look forward," "might," "should," and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: the advantages of seclidemstat (SP-2577) as a treatment for Ewing sarcoma, Ewing-related sarcomas, and other cancers and its ability to improve the life of patients; expected cohort readouts from the Company's clinical trials and expected therapeutic options for SP-2577 and related effects and projected efficacy, including SP-2577's ability to inhibit LSD1; the future of the company's Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the October 2022 suspected unexpected severe adverse reaction (SUSAR) event and resulting partial clinical hold by the U.S. Food and Drug Administration (FDA); the advantages of protein degraders including the value of SP-3164 as a cancer treatment; the timing of clinical trials for SP-3164 and expected therapeutic options for SP-3164 and related effects and projected efficacy; impact that the addition of new clinical sites will have on the development of our product candidates; the timing of our IND submissions to the U.S. Food and Drug Administration (FDA) and subsequent timing for initiating clinical trials; interim data related to our clinical trials, including the timing of when such data is available and made public; our growth strategy; whether the company will develop additional undisclosed cancer-fighting assets in the targeted protein degradation space; expanding the scope of our research and focus to high unmet need patient populations; and the commercial or market opportunity and expansion for each therapeutic option, including the availability and value of a pediatric priority review voucher for in-clinic treatments and potential for accelerated approval. We may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: Seclidemstat's impact in Ewing sarcoma and as a potential new and lesstoxic treatment; expected dose escalation and dose expansion; resolution of the FDA's partial clinical hold on the company's Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FETrearranged sarcomas following the SUSAR; our ability to resume enrollment in the clinical trial following its review of the available data surrounding the SUSAR; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials and regulatory submissions; the ability of, and need for, us to raise additional capital to meet our business operational needs and to achieve its business objectives and strategy; future clinical trial results and the impact of such results on us; that the results of studies and clinical trials may not be predictive of future clinical trial results; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; and other risks described in our filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. The forward-looking statements contained in this presentation speak only as of the date of this presentation and are based on management's assumptions and estimates as of such date. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K. You may access these documents for no charge at http://www.sec.gov. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or gualification under the securities laws of any such state or other iurisdiction.

Investment Highlights

Two compounds, each with numerous avenues to create shareholder value	 SP-3164: next generation protein degrader expected to enter the clinic in 2023 Seclidemstat (SP-2577): a clinical stage reversible LSD1 protein inhibitor
Multiple near-term milestones to catalyze awareness and build value	 SP-3164: Preclinical data in 2022, IND filing in 1H23 for hematologic or blood cancers and/or solid tumors Seclidemstat: interim clinical data, resolve partial clinical hold
Pipeline features new indications in large market opportunities	 Protein degradation builds on a 2021 \$16 billion global opportunity Protein inhibition immunotherapy combination and blood cancers represent compelling market opportunities
Management team and advisors experienced in bringing drugs to market	 Track record at large pharma and development-stage companies Includes Eli Lilly, Sanofi, Boehringer Ingelheim, GSK and AbbVie
Cash/equivalents of \$16.8 million as of September 30, 2022	 Funds operations through near-term milestones No debt, clean cap structure



Pipeline Overview

Protein Inhibition

- **Seclidemstat** is a novel oral, *reversible* LSD1 inhibitor in Phase 1/2 clinical trials for solid and hematologic cancers
- MDACC exploring potential larger market indications in hematologic/blood cancers
 - Trial enrollment is currently paused
- Potential for immunoncology combination therapy
- FDA designations for Ewing's sarcoma include:
 - Orphan drug designation grants additional market protection
 - Fast track status provides accelerated access to FDA and sets up potential speed to market for rare sarcoma indications
 - Rare pediatric disease, with possibility for a highly valuable priority review voucher (PRV)
 - Sarcoma trial is currently on partial clinical hold

Protein Degradation

- **SP-3164** is a next-generation cereblon-binding targeted protein degrader (molecular glue)
- Stabilized (S)-avadomide (CC-122) developed for comparable or superior efficacy, with improved safety
- First-generation avadomide demonstrated activity in hematologic malignancies and solid tumors in > 400 patients across 10 clinical trials
- Preclinical data package planned for 2H22
 - 5th Annual TPD Summit October 2022 completed
 - American Society of Hematology December 2022
- IND activation planned for 1H23
- Significant large pharma collaboration and acquisition activity validates technology potential

Product Pipeline

© 2022 Salarius Pharmaceuticals, Inc.

Overview

	Discovery	IND-Enabling	Phase 1	Phase 2	Phase 3	Next Milestones	
Sarcoma Program							
Ewing sarcoma (Seclidemstat + TC ¹)						Interim clinical data	
FET-rearranged sarcomas + Myxoid liposarcoma (Seclidemstat)						updates in 2H 2022 Resolution of Sarcoma program Partial Clinical	
Hematologic cancers ² (Seclidemstat + azacytidine)						Hold	
Select gynecologic cancers ³ (Seclidemstat + pembrolizumab)			•			Trial activation	
Hematologic and solid tumors (SP-3164)						Preclinical data in 2H22 Submit IND in 1H23	
Hematologic and solid tumors NCE second-generation LSD1						Nominate clinical candidate	
\							

¹ Topotecan and cyclophosphamide² Investigator initiated trial active at MD Anderson Cancer Center treating patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia³ Investigator initiated trial – Clinical trial agreement not yet finalized

5

SP-3164 Protein Degrader

A next-generation molecular glue (MG)

Targeted Protein Degradation Space Has Witnessed Tremendous Growth

Cumulative Capital Invested in Development of Targeted Protein Degrader Therapies^{1,2}

> (\$B) Number of Investments

Large Biopharma Companies Have Moved Aggressively to Gain Exposure³

Selected targeted protein partnerships and strategic collaborations since 2015




SP-3164

¹ Roots Analysis, ² Nature.com, ³ Cortellis.

7


Targeted Protein Degradation: A Long History with Recent Insights Driving Novel Drug Development

Targeted Protein Degradation (TPD) utilizes the **body's own** degradation system to **selectively eliminate** cancer-promoting proteins AND provide the ability to pursue historically **undruggable** cancer-promoting targets





Chirality Occurs in Nature & Therapeutics Left- or Right-Handedness Leads to Dramatic Differences




Hands & Chiral Compounds

non-superimposable mirror images (enantiomers)





S-Limonene Left-handed enantiomer




Orange Peel Oil

R-Limonene Right-handed enantiomer


Classic Chiral Switch Example: Celexa[®] ⇒ Lexapro[®] Improved Drug Profile with the Single, Preferred Enantiomer

Applied since the 1990s for racemic drugs with stable chiral centers




SP-3164 was Developed From, and Improves Upon, a Clinically Validated Compound

- SP-3164 was developed as a next-generation cereblon-binding version of a widely explored molecular glue, avadomide (Celgene, CC-122), that was studied in over 400 patients across 10 trials.
 - Avadomide (AVA) has an unstable chiral center and therefore exists as a racemic mixture: a 1-to-1 mixture of enantiomers (mirror images of one another). SP-3164 utilizes deuterium to lock the enantiomer in place and therefore exists as only the active, S-enantiomer with minimal interconversion.



Increased Anticancer Activity in Animal Models



The improved properties of SP-3164 translate to increased efficacy compared with R-enantiomer or with avadomide (racemic mixture)

© 2022 Salarius Pharmaceuticals, Inc.


SP-3164

54 Team & Milestones


Summar

1. Data on file 2. Jacques, et al., Proc Natl Acad Sci. 2015, 112(12), E1471-9.

SP-3164 Demonstrates Single-Agent Activity in DLBCL And Superiority To Lenalidomide (Revlimid®)



Degradation of Aiolos and Ikaros in tumors




- SP-3164 demonstrated pronounced antitumor activity as single agent outperforming lenalidomide and comparable to avadomide while SP-3165 lacked significant antitumor activity (**** p≤ 0.0001).
- Due to SP-3164's shorter $t_{1/2}$ vs. avadomide, SP-3164 was studied BID resulting in the largest inhibitory effect.
- Treatment with SP-3164 caused degradation of Aiolos and Ikaros in tumors (representative IHC images at t=6hr).

ones Summa

13

SP-3164, A Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models, American Society of Hematology (ASH) Annual Meeting December 11-14, 2022

SP-3164 Shows Synergistic Activity with Rituximab in DLBCL And Superiority To Lenalidomide plus Rituximab



- SP-3164 combination with rituximab was compared to approved regimen, lenalidomide and rituximab in WSU-DLCL2 DLBCL model.
- Combination of SP-3164 and rituximab (4 weeks of treatment) resulted in sustained regressions with 50% of mice being tumor-free, significantly better than the lenalidomide and rituximab regimen (****p ≤0.001).

© 2022 Salarius Pharmaceuticals. Inc.

Team & Mile


Summary

SP-3164, A Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models, American Society of Hematology (ASH) Annual Meeting December 11-14, 2022

SP-3164

SP-3164 Is The Preferred (S) Avadomide Enantiomer Compelling Avadomide Clinical Data Supports Sp-3164's Potential In DLBCL

Single agent activity in R/R DLBCL patients¹



Avadomide performed just as well or better than lenalidomide as it also showed activity in the GCB subtype. Avadomide Phase 1 data is comparable to what CC-99282 is showing in the ongoing Phase 1. Use of the genetic signature increase response rates.

Combination activity in frontline DLBCL patients²

	1 mg 2/3 wk (n = 4)	2 mg 2/3 wk (n = 11)	3 mg 2/3 wk (n = 11)	3 mg 3/3 wk (n = 8)	Overall* (N = 34)
ORR, % (95% CI)	75 (19.4-99.4)	82 (48.2-97.7)	100 (71.5-100)	88 (47.3-99.7)	88 (72.5-96.7)
CRR, % (95% CI)	50 (6.8-93.2)	82 (48.2-97.7)	91 (58.7-99.8)	75 (34.9-96.8)	79 (62.1-91.3)
Complete metabolic response, n (%)	2 (50)	9 (82)	10 (91)	6 (75)	27 (79)
Partial metabolic response, n (%)	1 (25)	0	1 (9)	1 (13)	3 (9)
Progressive disease, n (%)	1 (25)	1 (9)	0	0	2 (6)
1-Year PFS rate, % (95% CI)	80 (13-96)	80 (45-95)	NR	NR	80 (58-92)
Median follow-up duration, mo† (range)	12.9 (11.5-14.1)	11.4 (1.1-15.9)	9.9 (1.1-11.7)	6.8 (2.1-7.9)	10.2 (7.9-11.7)

Avadomide showed compelling activity in combination with R-CHOP at various dose schedules. The most compelling dose schedule 3 mg (2/3 wk) resulted in a 100% ORR and 91% CR.

Performed better than lenalidomide +R-CHOP (ROBUST trial, ABC Subtype): ORR: 91% and CR 69%

Based on published/presented studies
 Presented at ASCO 2020

SP-3164 Development Advantages & Value Inflection Points

Next-generation preclinical molecular glue and part of the growing targeted protein degradation field, with a...



De-risked profile due to the known data from the firstgeneration compound, including clinical data in more than 400 subjects...

With potential to treat both hematologic and



solid tumors with the first clinical trial expected to start in 2023

Upcoming value inflection points

- Preclinical data package in 2H 2022 demonstrating differentiation
- 2. IND submission in mid-2023
- Phase 1 study expected to begin in 2H 2023

Seclidemstat

A targeted reversible LSD1 inhibitor

Seclidemstat Reversibly Inhibits LSD1, A Validated Target

Seclidemstat is a Lysine Specific Demethylase 1 (LSD1) inhibitor that affects gene expression making it an attractive target for sarcomas and hematologic or blood cancers

LSD1 in No	LSD1 in Normal Cells and Cancer Cells ¹					
Normal Cells	 LSD1 is necessary for stem cell maintenance and cell development processes (e.g., blood cells) 					
Cancer Cells	 LSD1 is over-expressed LSD1 acts incorrectly to silence or activate genes leading to disease progression Validated target: LSD1 CRISPR deletion oftentimes detrimental to cancer cells 					

Companies with clinical LSD1 inhibitors:

Celgene Salarius IMAGO ORYZON RMACEUTICALS **Bristol-Myers Squibb** Seclidemstat © 2022 Salarius Pharmaceuticals. Inc.

Seclidemstat reversibly inhibits LSD1


preventing the growth of cancer cells

activity

Reverses incorrect gene expression, killing or

Inhibits both the enzymatic and the scaffolding

LSD1 Inhibitors Positively Impact Therapeutic Activity; Seclidemstat Demonstrates Broader Scaffolding Inhibition



Seclidemstat Sarcoma Program

Phase 1/2 in Ewing's sarcoma

Ewing's Sarcoma: Unmet Need, Meaningful Opportunity





~500 US patients diagnosed each year with a median age of 15 at the time of diagnosis

- 75% localized¹
- 25% with metastasis¹

Pishas, K. et al. (2016)

Standard-of-Care

Chemo

Surgery and Amputations

月

~40% of patients are refractory or relapse²

- 70-90% 5-year mortality rate²
- No standardized second-line treatment

² Van Mater, et al. Oncotargets (2019)

An effective, non-toxic, oral

Salarius' Vision

treatment

- Accelerated U.S. approval
- Rapid market uptake
- \$200M+ global sales³ (est.)
- Possible PRV worth \$80M-\$150M



Fast track designation

Orphan drug designation



Rare pediatric drug designation

³ Represents longer term vision and does not represent estimate of future performance, financial or otherwise. There is no assurance that we will achieve our longer-term vision.


2022 Salarius Pharmaceuticals. Inc.

Seclidemstat

Radiation

Seclidemstat Targets the Root Cause of Ewing's Sarcoma

Ewing's sarcoma is driven by dysregulation of gene expression



Second Line Ewing Sarcoma Patients (1st Relapse Patients) Had 7.4 Months Median Time To Tumor Progression (data on file)

Patients with Disease Control Had No Observed Disease Progression Interim Results of Salarius Sponsored Trial for Treatment Ewing Sarcoma (as 10/31/2022)

	CRc ¹	PRc ¹	ORR	SDc ¹	DCRc	PD	mTTP Months	Range Months
1 st Relapse Pts (5)	1	1	2 (40%)	1	3 (60%)	2	7.4	1.4 to 13.8
2 nd Relapse Pts (8)		1	1 (13%)	1	2 (25%)	6	1.5	0.7 to 5.1
1 st and 2 nd Relapse Pts (13)	1	2	3 (23%)	2	5 (38%)	8	1.6	0.7 to 13.8
1 st and 2 nd Relapse Pts w/ DCRc (5) 5 (38%)							7.4	3.1 to 13.8 No Observed PD ²
rEECur (primarily a 1 st relapse Ewing sarcoma data set ³) Salarius (Second Line or 1 st Relapse Patients)						3.5 mPFS 7.4 mTTP	95% CI 2.5 to 5.1	

¹ Patient status confirmed (c) by both C2 and C4 scans. ² Among 5 patients with DCRc while on study: 1 pt withdrew (WD) at 3.1 months with 32% PRc; 1 pt WD at 5.1 months with 11% reduction SDc due to a nondrug unrelated SAE; 1 patient WD at 7.4 months with CRc; 1 patient WD at 12.8 months with 80% PRc (elected RT consolidation treatment); 1 patient at 13.8 months continues treatment with SDc. ³ ~80% Primary Refractory or 1st Relapse Patients and ~20% 2nd Relapse Patients.



SP-3164

n & Milestones

mary

Abbreviations CR complete response; PR partial response; SD stable disease; DCR disease control Rate (CR, PR, SD); TTT Time to Tumor Progression; PFS Progression Free Survival

Sarcoma Phase 1/2 Clinical Trial Sites Are A Who's Who Of Cancer Research

Ewing's Sarcoma & FET-Rearranged Sarcomas

Open-label, **dose-expansion trial design**

- **Arm 1**: Up to 30 Ewing's sarcoma patients treated in combination with topotecan/cyclophosphamide
- Arm 2: Up to 30 FET-rearranged sarcoma patients (including up to 15 myxoid liposarcoma patients) treated with single-agent seclidemstat

Primary objective: Safety, tolerability Secondary objectives: Antitumor assessment Exploratory: cfDNA, CTCs, hemoglobin F, target engagement

Currently on Partial Clinical Hold





Manageable safety profile, pharmacokinetics support BID dose schedule



Signs of antitumor activity in patients at or below the RP2D in Ewing's and FET sarcomas


Seclidemstat Additional Indications

Hematologic malignancies and immunotherapy

Seclidemstat + Azacitidine Shows Activity In Cell Lines And MDACC Is Now Treating Patients With Hematologic Or Blood Cancers

Hematologic Cancers¹

Seclidemstat inhibits MDS cell growth and shows synergy with azacitidine



1. Seclidemstat + azacitidine trial is open for enrollment

Phase 1/2 investigator-initiated study enrolling patients at <u>MD</u> <u>Anderson Cancer Center</u> in myelodysplastic syndromes & chronic myelomonocytic leukemia

Clinicaltrials.gov Identifier: NCT04734990

Clinical data updates anticipated in 2H 2022

Patient enrollment is currently paused

Primary Objectives


- Safety, tolerability and maximum tolerated dose
- Overall response rate

Secondary Objectives

- Overall survival, duration of response, relapse-free survival, leukemia-free survival and safety
- Correlative studies including correlation of response with disease subtypes, genomic profile and *in vitro* studies

The Combination of Seclidemstat with Azacitidine Shows Initial Signs of Potential Activity Treatment of MDS and CMML

ASH Poster Presentation Results from the Ongoing Investigator Sponsored MD Anderson Trial for Treatment of MDS and CMML¹ with prior HMA² treatment



1 Patients previously failed azacitidine or decitabine. SCT: stem cell transplant, CMML: chronic myelomonocytic leukemia, MDS: myelodysplastic syndrome, T-MDS: therapy related MDS, mCR: marrow complete response, pCyR: partial cytogenetic response, SD: stable disease, PD: progressive disease, BM: bone marrow; HI: Hematologic Improvement; PI: Platelet improvement ² HMA Hypomethylating Agent (azacytidine, decitabine)

© 2022 Salarius Pharmaceuticals, Inc.

Seclidemstat


Team & Milestones

27

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, American Society of Hematology Annual Meeting December 11-14, 2022

Seclidemstat Analog Causes Increase In Immune Cell Infiltration In Organoids – Unmasks Hidden Tumors (turns cold tumors hot)

- Checkpoint inhibitors (CPIs) only work in 15%-60% of patients¹
- 7 FDA approved CPIs generated 2021 global sales of ~\$19.9 Billion with estimated annual growth of $\sim 20\%^2$
- Turning a cold tumor hot unmasks the hidden tumor allowing CPIs to attack the cancer
- A 1%-point increase in 2021 COI market share was worth \$200M in annual sales





HOT tumor: responsive to checkpoint inhibitor

COLD tumor: not responsive to checkpoint inhibitor

Orange/gold indicates anticancer immune cells are infiltrating tumor


1 (https://jitc.bmj.com/content/7/1/306)

2 (https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report)

3 Soldi, R. et a. AACR 2019

Planned Clinical Trial to Demonstrate Increased Response to Checkpoint Inhibitors

Seclidemstat could turn cold tumors into hot tumors...



...and may help increase patient response to IO therapies

Topper, M.J., et al. Nature Reviews (2019)

Market Opportunity

SPEED-TO-MARKET



Potential for accelerated approval, priority review

\$80M-\$150M

Pediatric priority review voucher (est.)

\$400M+

Global sales per year (est)¹

EXPANDING INTO LARGER MARKETS

PROOF-OF-CONCEPT IN HEMATOLOGIC CANCERS

Trial in MDS/CML initiated at MD Anderson Cancer Center



POTENTIAL TO ENTER INTO IMMUNOTHERAPY

Sensitizing resistant cancers to checkpoint inhibitors

\$1B+ Market Potential³


Citations in Appendix A

Value-Creating Near-Term Milestones

Protein Degradation

SP-3164 is a next-generation MG based on a drug studied in >400 subjects that showed compelling efficacy and safety

Next-generation MGs are building upon an established \$16.1B first-generation market



Protein Inhibition

Seclidemstat in Phase 1/2 clinical trials for sarcomas and hematological cancers (presently on partial clinical hold)

Speed-to-market in rare sarcomas (\$400M opportunity) + market expansion into larger markets (\$1B+ opportunities)

Seasoned Leadership Team



Board of Directors

David Arthur, MBA	Jonathan Lieber, MBA	Tess Burleson, CPA	Paul Lammers, MD MSc	Bruce McCreedy, PhD	William McVicar, PhD	Arnold Hanish, CPA
Salarius Pharmaceuticals	Danforth Advisors	Translational Genomics Research	Triumvira Immunologics	Myeloid Therapeutics	Neuromity	Omeros Corporation
	AGT Corporation	Institute	Merck Serono	Precision	Sepracor	Eli Lilly
0	Histogenics		Merck Serono	BioSciences	Novartis	
© 2022 Salarius Phari	maceuticals, Inc. Overvi	ew Seclidemstat	SP-3164 Team &	Milestones Summar	ту	31

Investment Highlights

Two compounds, each with numerous avenues to create shareholder value	 SP-3164: next generation protein degrader expected to enter the clinic in 2023 Seclidemstat (SP-2577): a clinical stage reversible LSD1 protein inhibitor
Multiple near-term milestones to catalyze awareness and build value	 SP-3164: Preclinical data in 2022, IND filing in 1H23 for hematologic or blood cancers and/or solid tumors Seclidemstat: interim clinical data, resolve partial clinical hold
Pipeline features new indications in large market opportunities	 Protein degradation builds on a 2021 \$16 billion global opportunity Protein inhibition immunotherapy combination and blood cancers represent compelling market opportunities
Management team and advisors experienced in bringing drugs to market	 Track record at large pharma and development-stage companies Includes Eli Lilly, Sanofi, Boehringer Ingelheim, GSK and AbbVie
Cash/equivalents of \$16.8 million as of September 30, 2022	 Funds operations through near-term milestones No debt, clean cap structure





Combination of Possibilities Presents Significant Market Opportunity for Seclidemstat

¹ Represents longer term vision and does not represent estimate of future performance, financial or otherwise. There is no assurance that we will achieve our longer term vision.
 ² Hematological Malignancies. Apr 2020. Brand Essence Market Research.
 ³ <u>https://www.forbes.com/sites/greatspeculations/2019/03/12/how-much-can-mercks-share-price-grow-if-keytruda-gets-10-share-of-oncology-drug-market/#77edba677e18
</u>

⁴Cancer of the Ovary – Cancer Stat Facts, The National Cancer Institute: Surveillance, Epidemiology and End Results Program

https://seer.cancer.gov/statfacts/html/ovary.html.

- ⁵ GlobalData: Prostate Cancer: Global Drug Forecast and Market Analysis to 2028
- ⁶ GlobalData and Epidemiology Market Size Database, TNBC
- ⁷ GlobalData: Opportunity Analyzer: Ovarian Cancer Opportunity Analysis and Forecast to 2025
- ⁸ Morel, D., et al. Ann of Oncology 2017



Avadomide (CC-122) was Studied in Several Clinical Trials and Demonstrated Compelling Efficacy and Safety

NCT number	Indications	Ν	Treatment	Results
NCT01421524 ¹	MM, DLBCL – at least 1 prior therapy, GBM, PCNSL, R/R HCC	271	avadomide	Completed DLBCL, 97 pts (one of the expansion cohorts) ORR: 28%; CR: 9% with gene signature ORR: 44%; CR: 16%
NCT03283202 ²	newly diagnosed DLBCL	35	avadomide + R-CHOP	Completed All cohorts: 88% ORR; 79% CR 3 mg 2/3 wk: ORR 100%; CR 91%
NCT02417285 ³	DLBCL – at least 2 prior therapies, iNHL – at least 1 prior therapy R/R FL (expansion)	75	avadomide + obinutuzumab	Not recruiting R/R FL 53 pts; DLBCL 19 pts; MCL 1 pt 66% ORR (FL only: 72%) 29% CR (FL only: 40%)
NCT02406742 ⁴	CLL/SLL – at least 1 prior therapy; dose escalation	47	avadomide (A), avadomide + ibrutinib (B), avadomide + obinutuzumab (C)	Completed A. 7% ORR B. 88% ORR C. 63% ORR
NCT02031419 ⁵	DLBCL – chemo refractory, FL – at least 1 prior therapy	174	avadomide + CC-223 +/- rituximab	Not recruiting DLBCL + rituximab 39% ORR, 16% CR (n=19) with gene signature: 50% ORR, 50% CR
NCT033106196	NHL, DLBCL, FL	~ 3	avadomide + JCAR017 (CAR-T-Cell therapy)	N/A
NCT02859324 ⁷	HCC – up to 2 prior therapies	21	avadomide + nivolumab	2 mg: 43% ORR, 72% DCR, PFS 4.3 mo 3 mg: 0% ORR, 44% DCR, 3.2 mo 4 mg: 0% ORR, 80% DCR, 4.1 mo
NCT02323906 ⁸	HCC – no prior therapy	12	avadomide + sorafenib	Terminated N/A
NCT038346239	Melanoma – CPI naïve or CPI progressed	23	avadomide + nivolumab	N/A

MM – multiple myeloma; DLBCL – diffuse large B-cell lymphoma; GBM – glioblastoma multiforme; PCNSL – primary central nervous system lymphoma; HCC – hepatocellular carcinoma; iNHL – indolent non-Hodgkin's lymphoma; FL – follicular lymphoma; CLL/SLL – chronic lymphocytic leukemia / small lymphocytic lymphoma; MCL – mantle cell lymphoma; R/R – relapsed or refractory; CPI – checkpoint inhibitor; R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; ORR – overall response rate; CR – complete response; DCR – disease control rate; PFS – progression-free survival; pt – patient. Table reflects Salarius's best efforts at capturing published data.